Triple-negative breast cancer (TNBC), characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and HER2, is often associated with a high risk of metastasis and recurrence, and there are only a few targeted therapies available for this aggressive form of breast cancer. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.